PT Organon Pharma Indonesia Tbk

scpi

Overview

SCPI Overview

PT Organon Pharma Indonesia Tbk is an Indonesia-based pharmaceutical company. The Company is engaged in the processing, packaging and development of pharmaceutical products for human and animal consumption, toiletries, cosmetics, household and related products. The Company is also engaged in importing of raw materials, finished goods and providing business and management consultancy services. The Company’s segments include Pharmaceutical Manufacturing and commercial. For women's health, the Company develops product specifically for women, including contraception, fertility, pregnancy management, perinatal diseases and other diseases.

5101520ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: SCPI

Watchlist
Market Cap.
IDR 104.00Billion

~$6.50M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

SCPI Valuation Metrics

29,000

IDR
0.0%

Closing Price on 2024-04-17

Price to Equity

0.44

P/E

At 0.44x P/E TTM, SCPI.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Price to Book

0.10

P/B

At 0.10x P/B TTM, SCPI.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Price to Sales

0.04

P/S

At 0.04x P/S TTM, SCPI.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Valuing PT Organon Pharma Indonesia Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Organon Pharma Indonesia Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
0.21x
Price/Forward Earnings
-
Enterprise Value/Revenue
-0.03x
Enterprise Value/EBITDA
-0.29x
PEG Ratio
0.01x

Analyst Ratings

No analyst ratings available yet.

Last closing: IDR29,0002024-04-17
IDR 586,136.48

Considerably Higher Intrinsic Value: Analyst's intrinsic value is of SCPI is IDR586,136, which is 1922% higher than SCPI's last closing price of IDR29,000 (as of 2024-04-17).

Valuation Recap of SCPI stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 0.44x is below the ID market average of 8.46x and is trading at a discount to peers in the Pharmaceuticals & Health Care Research sector (10.68x).

High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 0.10x is below the peers average of 1.15x in the Pharmaceuticals & Health Care Research sector. In fact, less than 25% of its peers trade at a lower P/B ratio than SCPI.

Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.04x is below the peers average of 0.71x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of SCPI's valuation relative to its current sales and future earnings growth.

Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. SCPI's P/CF ratio of 0.21x is considered healthy by analysts.

Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. SCPI's EV/R ratio of -0.03x is considered extremely underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.40x.

Medium
Considerably Higher Intrinsic Value: Analyst's intrinsic value is of SCPI is IDR 586,136.48, which is 1922% higher than SCPI's last closing price of IDR 29,000.00.

Peers

SCPI Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk65.45T27.06T 30.45T 2.77T 23.663.06
MIKAPT Mitra Keluarga Karyasehat Tbk.36.85T7.34T 4.26T 0.92T 40.236.33
SILOPT Siloam International Hospitals Tbk.31.10T10.98T 11.19T 1.21T 25.683.93
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.61T 2.50T -0.04T -534.7211.09
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk19.95T3.89T 3.57T 0.95T 20.995.89
HEALPT Medikaloka Hermina Tbk.16.86T8.80T 5.78T 0.44T 38.544.36
PRAYPT Famon Awal Bros Sedaya Tbk9.56T4.70T 1.84T 0.22T 44.073.42
TSPCTempo Scan Pacific Tbk8.66T11.32T 13.12T 1.18T 7.351.12
SOHOPT Soho Global Health Tbk6.24T4.75T 8.20T 0.37T 16.822.60
KAEFKimia Farma Tbk.4.37T8.99T 10.19T -0.17T -26.25
Competitiveness Recap of SCPI stock
WeightNotesScore
High
At a market cap of IDR 104.00 billion, SCPI.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.

High
At a PE of 0.44, SCPI.JK ranks 9 out of 10 companies in the Healthcare sector for P/E value. The average PE is -31.69 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (44.07) in the Healthcare sector.

Medium
At a PE of 0.44, SCPI.JK is trading at a lower PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 10.68). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.

Medium
At a revenue of IDR 2.84 trillion, SCPI.JK ranks 8 in Revenue out of 10 companies in the Healthcare sector.

Medium
At a profit of IDR 0.24 trillion, SCPI.JK ranks 8 in Profit out of 10 companies in the Healthcare sector.

Future

Future Growth of SCPI

Growth Forecasts

No data available

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are growing at a projected rate of 7.12% against the IDX average of +7.6%.

Pharmaceuticals & Health Care Research sector overview
No data is available for SCPI at the moment.
Future growth prospect of SCPI
WeightNotesScore
High
SCPI's projected growth rate of 7.12% is below the ID market average of 7.62%.

High
The Pharmaceuticals & Health Care Research sub-sector is projected to shrink revenue by -5.79% in 2024. This number is higher than the previous year 2023's growth rate of -24.01%. false

Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to decrease earnings by 0.00% in 2024. This number is lower than the previous year 2023's EPS growth of 0.00%. false

Medium
SCPI and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a challenging year heading into 2024. Specifically, earnings are projected to decrease by 0.00% in 2024 while revenue growth is projected to decrease by -5.79%. These macroeconomic trends will likely be a headwind for SCPI's earnings growth prospects in the next 2 years.

Loading...
Loading...

Management

Executive Management

President Director

Daniel15.2 years
Yuliana
Director
Andri Soelastyo
Director
NamePositionShares%
No data is available for SCPI at the moment.
Expressed in millions IDR, unless otherwise stated

Ownership

SCPI Ownership

NameNumber of SharesOwnership (%)Value
Organon Llc3,556,33698.79103.13B
No data is available for SCPI at the moment.